Trial success for Tryton's bifurcation stent
This article was originally published in Clinica
Executive Summary
A trial assessing the Tryton side branch stent as a treatment for atherosclerosis in bifurcated blood vessels has posted "impressive data".
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.